2023 Obesity Fellows Program
(3)
Image For Activity Cover
Availability
On-Demand
6 Courses
Expires on Dec 31, 2024
Cost
$0.00
Credit Offered
3 AMA PRA Category 1 Credits
3 ABIM-MOC Points
3 Participation Credits
  • Course Description
  • Target Audience
  • Learning Objectives
  • Accreditation Statement
  • Faculty and Disclosures
  • Recommended

Chaired by renowned obesity medicine expert Amy Rothberg, MD, DABOM, the Obesity Fellows program aims to give these health care practitioners (HCPs) the confidence, resources, and experience needed to treat patients who are living with the chronic condition of obesity. 

Embark on a comprehensive learning journey with our on-demand course, featuring six distinct pre-recorded lectures, each accompanied by pre and post-tests, along with insightful recordings. To earn credit for each lecture, participants must complete a minumum of three modules. In order to complete a module, you must achieve a minimum score of 60% on the post-exam to claim CME credit and MOC points. If participants do not achieve a minimum score of 60%, they have the option to change their answers and make additional attempts to achieve a passing score.

The intended audience for this program is endocrinology fellows, but non-fellow endocrinologists will also benefit from education in this rapidly evolving area.
Upon completion of this activity, learners will be able to:
  • Discuss obesity as a multifactorial, chronic, complex disease, strategies for opening discussions about obesity, and the effect of weight bias on patients.
  • Apply updated knowledge of obesity pathophysiology when developing treatment plans.
  • Evaluate recommendations for specialized diets, physical activity, and other behavioral changes for weight management.
  • Manage anti-obesity medications to achieve sustained weight loss and reduce the risk of comorbid disease, paying particular attention to short- and long-term management concerns.
  • Discuss the risks and benefits of weight loss procedures and surgeries.

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the the Endocrine Society. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians. 

AMA PRA Category 1 Credit

The Endocrine Society designates each activity in this course for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.


Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.


Maintenance of Certification (MOC)
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 3.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


For questions about content or obtaining CME credit, please contact the Endocrine Society at info@endocrine.org

STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.

DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

  • Jaime Almandoz, MD: Novo Nordisk, Advisory Board/Consulting; Eli Lilly, Advisory Board/Consulting; Boehringer Ingelheim, Independent Contractor 
  • Jamy Ard, MD: Nestle Healthcare Nutrition, Consulting, Research Support; Novo Nordisk, Consulting; Boehringer-Ingelheim, Consulting, Research Support; Epitomee Medical, Research Support
  • Ania Jastreboff, MD, PhD: Novo Nordisk, Faculty, Research Grant Support; Eli Lilly, Advisory Board/Consultant, Research Support; Intellihealth, Advisory Board/Consultant, obesity treatment platform; Boehringer Ingelheim, Consultant, stock options; Scholar Rock, Consultant; Pfizer, Consultant; American Diabetes Association, Advisory Board/Consultant; NIH/NIDDK, Research Support
  • Jonathan Purnell, MD: Novo Nordisk, Advisor Global Obesity Program; Luciole Pharmaceuticals, Scientific Advisor
  • Domenica Rubino, MD: Novo Nordisk, Investigator (Institutional), Speaker, Consultant/Scientific Advisor, writing support; Boehringer Ingelheim,  Investigator (Institutional), Consultant, advisor; Epitomee Medical, Investigator (Institutional); Astra Zeneca, Investigator (Institutional); Eli Lilly,  consultant; Prime Therapeutics, speaker; Medscape/WebMD, speaker
  • Taraneh Soleymani, MD: Novo Nordisk, Speakers Bureau
  • Amanda Velazquez, MD: Weight Watchers, Advisory Board; Novo Nordisk, Consultant; Intellihealth, Advisory Board 

 

The following faculty reported no relevant financial relationships: Amy Rothberg, MD; Michael Weintraub, MD

The following committee member who reviewed content for this activity reported relevant financial relationships: Dimpi Desai, MD

The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.


ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by educational grants from Lilly and Novo Nordisk.

   
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
      
   
Android App Download IOS App Download Powered By